| Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding |
The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:
|
|
|
December 31,
|
|
|
|
|
2020
|
|
|
2019
|
|
|
Outstanding stock options
|
|
|
830,343
|
|
|
|
526,070
|
|
|
Outstanding restricted stock units
|
|
|
29,087
|
|
|
|
96,637
|
|
|
Warrants to purchase common stock associated with June 2016 Public Offering
|
|
|
421,867
|
|
|
|
421,867
|
|
|
Warrants to purchase common stock associated with March 2018 Public Offering - Series 2
|
|
|
798,810
|
|
|
|
798,810
|
|
|
Warrants to purchase common stock associated with December 2019 Public Offering
|
|
|
4,472,205
|
|
|
|
4,472,205
|
|
|
Option to purchase common stock associated with December 2019 Public Offering
|
|
|
—
|
|
|
|
583,333
|
|
|
Warrants to purchase common stock associated with December 2020 Public Offering - Series 1
|
|
|
6,800,000
|
|
|
|
—
|
|
|
Warrants to purchase common stock associated with December 2020 Public Offering - Series 2
|
|
|
6,800,000
|
|
|
|
—
|
|
|
For possible future issuance for the conversion of the March 2019 Notes
|
|
|
1,138,200
|
|
|
|
1,138,200
|
|
|
For possible future issuance for the conversion of the April 2020 Notes
|
|
|
1,299,790
|
|
|
|
—
|
|
|
Warrants to purchase common stock associated with Solar loan agreement
|
|
|
12,243
|
|
|
|
12,243
|
|
|
Total
|
|
|
22,602,545
|
|
|
|
8,049,365
|
|
|